Clinical Trial

Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Randomized, double-blind, phase 2b trial to assess comparability in immunogenicity, safety, and reactogenicity of MVA-BN vaccine manufactured in primary chicken embryo fibroblast (CEF) cells and the CCX.E10 quail cell line in adults
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-09-22; most recent amendment 2026-04-02.
Status change: Recruiting → Active, Not Recruiting 2026-04-02
Status change: Not Yet Recruiting → Recruiting 2025-10-27
Trial Details
NCT Number NCT07199569
Lead Sponsor Bavarian Nordic
Collaborators: ICON plc
Conditions Monkeypox (Mpox)
Enrollment 970 participants
Start Date 2025-10-27
Primary Completion 2026-11-30 (estimated)
Study Completion 2026-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-08